Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); Awaiting TIVO-1 ASCO Presentation
Tweet
Share
E-mailGet Alerts AVEO Hot Sheet
Price: $15.00 --0%
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO) price target of $28.00.
Analyst, George Farmer, said, "Although details remain undisclosed, management expresses high confidence in the data strength of TIVO-1, AVEO’s Phase III registration trial designed to support regulatory approval of lead asset tivozanib as front-line treatment of metastatic renal cell carcinoma (RCC). Recall top-line results revealed last month indicated that TIVO-1 met its primary endpoint of PFS improvement relative to approved RCC drug Nexavar. T-nib tolerability was comparable to what was observed in Phase II, per press release, which supports our view that t-nib may be the safest of its class. We believe this data will suffice for U.S. and EU regulatory approvals, which we model in 2013 and 2014, respectively."
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $12.80 yesterday.
Analyst, George Farmer, said, "Although details remain undisclosed, management expresses high confidence in the data strength of TIVO-1, AVEO’s Phase III registration trial designed to support regulatory approval of lead asset tivozanib as front-line treatment of metastatic renal cell carcinoma (RCC). Recall top-line results revealed last month indicated that TIVO-1 met its primary endpoint of PFS improvement relative to approved RCC drug Nexavar. T-nib tolerability was comparable to what was observed in Phase II, per press release, which supports our view that t-nib may be the safest of its class. We believe this data will suffice for U.S. and EU regulatory approvals, which we model in 2013 and 2014, respectively."
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $12.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Deere (DE) PT Raised to $585 at JPMorgan
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
